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Retinitis Pigmentosa (RP) is a group of hereditary genetic disorders, all causing 
degradation of the retina through loss of rod photoreceptor cells, ultimately causing loss 
of vision and in many cases complete blindness. Despite the prevalence of Retinitis 
Pigmentosa disorders, safe and effective treatment methods have not yet been approved 
to stop or regain vision loss in patients diagnosed with RP. However, the ophthalmic field 
as a whole is working on several new technologies and procedures in order to both slow 
loss of vision as well as potentially regain lost sight. In this thesis, I describe the genetic 
causes and effects of retinitis pigmentosa, followed by an analysis of current 
experimental treatments. Possible treatments were screened based on the following 
criteria; potential release date, adverse effects, ability to treat children, convenience, and 
the exclusion of patients for each therapy. Finally, I lend to support my claim that stem 
cell therapy by mesenchymal stem cells through intravenous infusion appears to be the 
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Retinitis Pigmentosa or RP refers to a group of inherited conditions all resulting 
in a gradual progressive reduction of vision through the loss of light-sensing cells of the 
retina (Zhang, 2016). Disorders of the eye, related to RP can be caused by variations in 
any of 60 genes that affect the retina, these variations lead to the eventual death of 
photoreceptor cells and pigmentation abnormalities. The differences in the degree of 
vision loss experienced by an individual correlates to the number of retinal cell deaths, 
with complete blindness being uncommon (Daiger, 2007). Retinitis pigmentosa disorders 
are hereditary. The gene affected often influences the speed of photoreceptor cell loss, 
level of progression, and displayed symptoms (Zhang, 2016). However, the typical 
progression regardless of other factors is as follows; loss of night vision (night blindness), 
blind spots in peripheral vision, loss of peripheral vision, and effects to central vision 
which often impairs tasks such as reading, driving, and recognizing faces (Birtel et al., 
2021). Some patients can retain cone photoreceptor cells if disease progression is slow 
enough as to not induce catastrophic damage to the rest of the eye, additional some 
patients' photoreceptor loss is slow enough that they will not reach blindness before end 







 The disease primarily affects three related components of the eye; the general 
retina, photoreceptor cells, and the retinal pigment epithelium (RPE). The retina is 
located at the back of the eye and is responsible for the detection of both light intensity 
and color. It is constructed of millions of light-sensitive cells called photoreceptors. Once 
fully developed, the photoreceptor cells cannot regenerate if damaged, leading to a 
progressive loss of function in each affected photoreceptor. With the substantial loss of 
photoreceptor cells the retina becomes unable to function properly leading to an inability 
to process and transmit sight information to the brain (Zhang, 2016). There are two types 
of photoreceptor cells: rods, which allow for light signaling, and cones which are 
responsible for fine detail and color, together they perform phototransduction which 
converts light to signals that can stimulate biological processes (Molday & Moritz, 2015). 
These structures are supported by the pigment epithelium, a pigmented layer of cells next 
to the retina which serves as a barrier between photoreceptors and a layer of blood 
vessels. The role of the RPE is to nourish the nerve tissue of the retina and maintain its 
health (Klimanskaya, 2006). When photoreceptors die, imbalances within the eye begin 
to occur, including oxidative damage. This oxidative damage can harm the pigment 
epithelium and cause significant risk for photoreceptor cell death due to lack of 
nourishment.  
Phototransduction  
 The above structures are critical to an early stage of vision that contributes to our 
visual processing system termed phototransduction. In this process, photoreceptor cells 




perception to the brain. This is accomplished as photoreceptor cells are stimulated by the 
intensity of light. After light is absorbed by a photoreceptor its cell membrane 
hyperpolarizes thereby reducing the rate of transmitter release. In dark conditions, the 
photoreceptors are depolarized, and the rate of transmitter release is high. Change in 
polarization is facilitated in the cell by ion channels permeable to Na+ and Ca++ in the 
outer segment of the membrane. As light is introduced, the channels close, allowing 
hyperpolarization to occur, thus reducing transmitter release to the photoreceptor 
synapse. cGMP levels regulate the opening and closing of the channels. In darkness, 
cGMP levels are high, keeping channels open whereas when exposed to light, levels 
drop, and channels begin to close. Photons create the cascade that reduces cGMP levels 
mediating the rate of the photo transmitter release. The photon will first be absorbed by a 
photopigment, rhodopsin, containing a light-absorbing chromophore, in the receptor disk 
of the cell. After absorbing the photon, a conformational change will occur triggering a 
series of alterations in the protein component of the molecule. The alteration activates the 
intercellular messenger transducin. Transducin then activates a phosphodiesterase that 
hydrolyzes cGMP lowering its concentration therefore reducing its binding ability to the 
channels, which keep them open (Stryer, 1983). The transmitters previously mentioned 
signal the numbers of photons absorbed thereby communicating the quality and quantity 
of light by graded membrane polarization to bipolar cells also housed in the retina, 
bipolar cells can then communicate with the ganglion and amacrine cells of the brain (Li 
et al., 2012). When photoreceptors are damaged or lost due to retinitis pigmentosa 
conditions, this photoreceptor-bipolar-ganglion cellular pathway is first dampened and 




serve phototransduction functions. RP-related diseases often attack the rod cells first 
which lie on the periphery of the eye, leading to loss of peripheral vision and producing 
tunnel vision in early stage patients. Since both rod and cone cells complete 
phototransduction, a patient can still have some vision even after all rod cells are lost. 
However, complications of rod cell death often trigger the death of cone cells as well, 
leaving no remaining cells with the ability to photo-transduce signals.  
Hereditary Development 
 Retinitis Pigmentosa, because of its serious hereditary influences on retinal 
development, greatly complicates any possible treatments. First, the disease can arise 
from a number of genes, many of which have not yet been identified, leading to 
complications in the diagnostic process and application of appropriate treatments.  
Additionally, retinitis pigmentosa can arise through several modes of inheritance making 
diagnoses increasingly difficult, as well as result from several different mutations on the 
same gene which add to the incredibly large number of variations the disease may take 
on. Each gene associated with the disorder is directly linked to photoreceptor cells, 
affecting structure and or function of the cell in some capacity. When mutations arise 
within these genes a gradual loss of photoreceptor cells in the retina begins, therefore 
characterizing the disorder (Fahim et al., 1993).  
The current modes of inheritance causing disorders connected to RP include; 
autosomal dominant which can result from a single inherited dominant mutated allele, 
autosomal recessive or requiring a mutated allele from both parents, X-linked which stem 
from mutation on an expressed X chromosome, or mitochondrial occurring through 




indicated which are categorized as isolate (Phelan, Mol Vis 2000; 6:116-124., n.d.). This 
heterogeneity makes not only determining which gene is affected incredibly difficult, but 
also genetic counseling and approaches for gene therapy.  
 Research on this topic has exponentially increased in recent years with several 
dozen teams across the world attempting to identify the genetic roots of RP. However, 
only 56 of the estimated 70 or more genes which may cause these disorders have been 
identified, making it possible to detect the specific mutations in only 30-80% of cases 
(Phelan, Mol Vis 2000; 6:116-124., n.d.) (Daiger et al., 2013). Utilization of deep 
sequencing or next-generation sequencing (NSG) has aided researchers in the discovery 
of new genes causing RP. As well, several of the diseases overlap with one another and 
single gene mutations have been found to cause multiple diseases, this is exemplified by 
the fact that some identical mutations have been found to manifest and produce different 
clinical findings. The heterogeneous nature of RP causes greater confusion as RP can 
arise from over 3,100 mutations across more than 50 genes. RP is defined as genetically, 
allelically, phenotypically, and clinically heterogeneous, this creates substantial 
confusion for clinicians and researchers desperately attempting to diagnose and create 
new treatment approaches (Daiger et al., 2013).  
Genes Discussed in Experimental Treatments 
PDE6A and PDE6B Mutations.  
 Both PDE6A and PDE6B are catalytic subunits of phosphodiesterase 6 (PDE6), a 
holoenzyme located in the integral membranes of retinal photoreceptors, responsible for 
the reduction of cytoplasmic levels of cyclic guanosine monophosphate (cGMP). While 




PDE6B are unknown and therefore they are often discussed in tandem (Muradov et al., 
2010). When this enzyme is lost due to mutation of the gene producing PDE6A or its 
subunits, persistent and chronic elevated cGMP levels can occur (STZ eyetrial, 2020). As 
a result of elevated cGMP increased calcium concentrations begin to flow into the cell 
causing the hyperactivation of cell death pathways, therefore contributing to the death of 
photoreceptor cells. Additionally, due to cGMP’s role in phototransduction, high levels 
can lead to problems in the process of visual signal transmission and amplification when 
incorrect concentrations are present therefore disrupting the phototransduction process 
and ability to convert light signals into sight (PDE6A Phosphodiesterase 6A [Homo 
Sapiens (Human)] - Gene - NCBI, n.d.). 
 Rd1 Mice. The Rd1 mouse was created in order to model autosomal recessive RP 
patients, so researchers could utilize them in retinitis pigmentosa experimental testing. In 
order mimic this form of RP, the mice are genetically modified for a mutation that affects 
the “expression of the β subunit of phosphodiesterase 6 (PDE6) leading to accumulation 
of cGMP that is thought to trigger rod photoreceptor degeneration (Kalloniatis et al., 
2016).” These mice are used in several methods of experimental testing including those 
that target the specific mutation and others such as antioxidant treatments and stem cell 
therapies which attempt to combat the harmful cascade created in the eye when 
photoreceptors begin to die.  
PRGR Gene Mutation 
RPGR gene mutations account for about 10 -15% of RP cases and approximately 
70% of X-linked RP cases. Despite its prominence, the mechanism which results in 




2019). It is currently known that the gene functions to provide instruction for protein 
creation necessary for normal vision, however, the protein products function is still 
unknown. Studies suggest that the protein created is integral to cilia function, which 
assists in the perception of vision. One protein segment created by RPGR is as the 
ORF15 exon, this exon or protein, is expressed solely in the retina and within 
photoreceptor cells. It has been suggested that the protein product may regulate the 
function of cilia which are thought to play a role in maintaining photoreceptors (RPGR 














RETINITIS PIGMENTOSA TREATMENTS  
Current Treatment  
 Unfortunately, due to the heterogeneity listed above, learning about both RP and 
its effective forms of treatment has been extremely difficult. Currently treatment for those 
who are diagnosed are based on palliative care and helping those with the disease to 
maintain the best standard of living possible with loss of vision and blindness. No FDA 
approved treatments have been found to stop disease progression or return lost vision. 
Until a cure is found clinicians will continue to administer standard palliative treatments 
recommended by the National Eye Institute including; receiving care from occupational 
therapists, orientation and mobility specialists, and certified low vision therapists. 
Patients are also evaluated and administered low vision aids such as special lenses, 
computer text programs, closed circuit television, and portable lighting. Vitamin A 
treatments and the implementation of Argus II, an electrode which helps relay 
information to the brain, have been used in late stage retinitis pigmentosa patients in 
which the electrodes probable benefits outweigh potential harm from the device (Retinitis 
Pigmentosa | National Eye Institute, n.d.).  
Experimental Treatments 
 Just as the disorder is complex and diverse, the experimental treatments being 
explored are as well. Treatments currently being studied range widely and aim for 




restoration of vision. Currently, Vitamin A supplements and Argus II implementation are 
becoming more widely used methods of treatment. However, these treatments are unable 
to stop the disease progression or restore lost vision. The procedures discussed in this 
section are working towards vision and photoreceptor restoration. With further 
exploration, scientific advances could begin to restore lost sight in retinitis pigmentosa 
patients.  
 The following treatments were selected for based on both the most recent 
experimentation while taking into consideration mutation and method diversity. The 
following studies range in treatment for most retinitis pigmentosa patients to highly 
targeted methods such as those focused on the Pdea6 gene and X-linked cases. Each 
study also utilizes a different form of potential intervention including antioxidants, 
optogenetics mediated gene therapy, subretinal injection, sub-tenon injection and 
intravenous infusion. While only three of these potential treatment methods focus on 
human studies, due to lack of trials which have reached this phase of testing, animal 
models such as the Rd1 mice, college surgeon rats, and mutated dogs can serve 
researchers in gaining valuable insights and data on how these treatments may affect the 
human eye with similar mutations.  
Antioxidant Treatments  
 Oxidative Stress and Retinitis Pigmentosa. As previously discussed, Retinitis 
Pigmentosa is a genetic disorder, which can be induced by a number of differing gene 
mutations leading to the loss of photoreceptor cells in the eye. Due to the clinical 
symptoms, it has been deduced that the rod photoreceptors which account for 95% of all 




symptoms while the central vision cones are maintained. However, over time complete 
blindness can occur which is thought to be the result of oxidative stress related to 
photoreceptor cell loss. A catastrophic cascade is induced when rod cell death begins, 
rods are responsible for metabolizing excess oxygen and as they are reduced a buildup of 
oxygen occurs with fewer cells capable of metabolizing it, therefore this loss of cells 
causes toxic oxidative stress to the entire system. This cascade was summarized as “a 
cascade of molecular phenomena—such as para-inflammation, synaptic impairment, 
apoptosis, and cell death—which hugely impact visual function, is triggered (Limoli et 
al., 2020).” As more rod cells continue to die from both the disease and now present 
oxidative stress even more excess oxygen is accumulated which eventually begins to 
cause cone cell apoptosis and total vision loss. While the body does have mechanisms in 
place to alleviate oxidative stress, the rapid loss of cells creates an insurmountable 
environment imbalance, often the retinal pigment epithelium is also damaged by the rod 
loss and subsequent oxidative damage. Transduction pathways and gene expression are 
also affected by oxidative stress damaging all cellular components including 
phospholipid membranes, proteins, and nuclear and mitochondrial DNA causing even 
more damage to the photoreceptors and RPE (Komeima et al., 2007). At this point retinal 
autophagy to catabolize the oxidatively damaged proteins and organelles may occur, but 
this can cause a buildup of autophagosomes, which deliver engulfed substrates into 
lysosomes for degradation. This leads to continued and increasing stress which only 
harms cells further, leading to apoptosis of all cells within the system, including the 





Antioxidant Treatments in Mouse Models of Retinitis Pigmentosa.  
Antioxidant treatments are attractive as they may not require gene specific 
approaches to help delay the loss of photoreceptors. However, these treatments must 
begin before any significant loss of photoreceptors to be effective. This treatment could 
substantially decrease the amount of oxidative pressure on the eye therefore increasing 
the chances of survival of the remaining rods and cones. In the following study conducted 
by John Hopkins School of Medicine, antioxidant “cocktails'' were administered to 
several different testing mice to see the effects on different variants of hereditary retinitis 
pigmentosa (Komeima et al., 2007).  
Prior to the above study, the slowing of RP through the use of antioxidant 
“cocktails” had been achieved in Rd1 mice. These mice are genetically mutated to model 
rapidly progressive recessive RP. The Rd1 mice treated with antioxidant cocktails 
produced results which indicated a slowing of the progression of rod cell death and 
reduction in oxidative damage. Therefore, the treatment created a better environment for 
the maintenance of cone cells (Sanz et al., 2007). The Hopkins study explored if similar 
methods could be effective for other models of RP, therefore, they used both Rd10/Rd10 
and Q344ter mice. Rd10/Rd10 mice house a mutation on the same gene as Rd1 mice, 
however they provide a model for more slowly progressive RP, while Q344ter mice carry 
the mutation of many patients with rapidly progressive dominant RP. While results varied 
between the mice, both showed positive results. The Rd10/Rd10 mice exhibited a 
slowing of both cone and rod cell death as well as preservation of photoreceptor function. 
In the Q344ter mice, there was not significant slowing of rod death, likely due to the 




density was significantly greater in antioxidant treated mice. This finding suggests that 
cone death is a result of oxidative damage as well as that it can be mediated with the 
correct combination of antioxidants (Komeima et al., 2007).  
Vitamin A Palmitate Antioxidant in Human Trials. Vitamin A Palmitate trials are 
currently being conducted in order to see if its antioxidant properties can produce slowing 
of rod photoreceptor deaths and survival of cone cells by diminishing oxidative stress. 
These trials are currently being conducted in humans and have produced a wide variety of 
results, with differing validity values concerning if rod cell death is being slowed. 
Clinical researchers appear to have differing opinions on the vitamins ability to slow the 
effects of RP including retinal loss of function in adults (Berson et al., 2018). No 
conclusive evidence has been found on its ability to slow rod cell degradation or protect 
cones from oxidative stress. Studies in children also show no conclusive results 
(Schwartz et al., 2020). 
 








 Optogenetics- Mediated Gene Therapy. Unlike potential antioxidant therapies 
optogenetic – mediated gene therapy is highly targeted, however, if successful it could 
bring treatment to a large division of RP patients. This therapeutic approach is currently 
being investigated in the same Rd1 mice used in antioxidant studies who have a 
“mutation of rod cGMP- specific 3′,5′-cyclic phosphodiesterase subunit beta (PDE6B) 
gene related to the hydrolysis of cGMP”, a mutation similar to many human patients 
suffering from autosomal recessive RP (Tomita & Sugano, 2021). 
 One form of gene therapy is transducing ChR2 or Chlamydomonas- derived 
channel rhodopsin -2, into differing order neurons. Several studies were summarized each 
producing greater light stimulation after gene-mediation. When the retinal ganglion cells 
were targeted in Rd1 mice, visual responses were restored. The same phenomenon 
occurred when Royal College Surgeons rats, which have similar mutations to Rd1 mice, 
were treated with an adeno-associated virus- mediated ChR2 gene transferred into 
ganglion cells. Additionally, reports of restoration of vision have been found in Rd1 mice 
in which the gene was transduced into the second order neurons, or bipolar cells, which is 
thought to contribute to the restoration of connection in the phototransduction pathway. 
While still in preliminary phases, researchers hope to transduce the gene into third-order 
ganglion neurons, which would restore visual functioning of any surviving retinal 
neurons. Clinical trials have begun using ChR2 in RP patients in the United States.  
 Despite the considerable promise of ChR2 – gene therapy, multiple limitations of 
the therapy were cited. These included low light and wavelength sensitivity which 




to activate the cells toxic effect on native photoreceptor cells. Additionally, most objects 
reflecting wavelengths below 550nm appeared blue to the small animal treatment 
subjects. Due to these limitations, another gene therapy is being studied using mVchR1 
or Volvox- derived ChR1, which has a broader, red- shifted action spectrum potentially 
allowing RP patients to see a broader range of colored objects. In this form of gene- 
mediated therapy, blind rats were treated with AVV vectors and stimulus was recorded at 
468nm of LED, therefore indicating a broader range of color could be seen with this 
treatment (Tomita & Sugano, 2021). 
 AAV- Pde6a Gene Therapy in Large Animals. Researchers at the University of 
Florida College of Medicine were also interested in AVV vectors, however, they decided 
to isolate the PDE6A gene in order to produce positive results of photoreceptor survival. 
Mutations in the alpha or beta subunits of the rod phosphodiesterase (PDE6) result in 
autosomal recessive RP, and each of these mutations respectively account for 
approximately 4% of patient cases or 8% together. Ten PDE6A mutant dogs were studied 
and received subretinal injections using Pde6a delivery by capsid – mutant adeno- 
associated virus serotype 8 (Mowat et al., 2017). Prior attempts with AVV serotype 5 
gene augmentation therapy were unsuccessful, however they prompted the researchers to 
develop this therapy. It was hypothesized that delivery of the treatment needed to be 
conducted as the eye was still developing and the use of highly efficient, rapid- onset, 
viral vectors was necessary (Mowat et al., 2017). Thus, the dogs were injected at a mean 
of 36 days of age, while their eyes had not yet fully developed, with one eye injected with 




The dogs were monitored over four months with several forms of retinal testing 
for thickness and light responses, as well as participating in tunnel mazes with both their 
injected and uninjected eyes separately. After testing was completed, the dogs were 
euthanized, and their retinas preserved for further testing unable to be done on a living 
eye. The study produced positive results in almost every testing field, however, some 
adverse effects were observed in the treated areas. The results included improvement to 
dim light vision as measured by electroretinographic testing, preserved photoreceptor 
layer thickness, evidence of rod function, improved survival of both rods and cones, and 
return of appropriate rhodopsin localization. Unfortunately, persistent regions of retinal 
separation and rosette formation occurred in both the AAV-Pde6a and control vector 
injected regions, suggesting a flaw in administration method rather than the injected gene 
(Mowat et al., 2017). 
 Initial X-linked Gene Therapy Results in Humans. Clinical trials have begun 
using similar methods to those in the previous study, initial findings support that with the 
use of sub-retinal injected adeno-associated viral vector encoding codon optimized 
human RPGR (AAV8-coRPGR) gains in visual functioning can occur. However, the 
requirements for eligibility in this treatment are incredibly specific and only proved 
positive results for six out of eighteen male participants, all suffering from a form of X-
linked retinitis pigmentosa resulting from RPGR gene mutation. While the results of this 
study were varied and six patients had increased visual performance, it was determined 
through this study the “mid-dose” range of the vector was most successful without 
causing negative effects related to inflammation (Cehajic-Kapetanovic et al., 2020).  




 Management of Retinitis Pigmentosa by Wharton’s Jelly derived Mesenchymal 
Stem Cells (MSC’). One of the most promising methods of photoreceptor preservation 
thus far has been the use of mesenchymal stem cell injection into the sub-tenon space 
which revives dormant cells and can halt the effects of retinitis pigmentosa symptoms 
within the retina. In this study, 32 patients in differing stages of retinal decline and 
suffering from different forms of retinitis pigmentosa, received injections of MSC’s. The 
stem cells were acquired from a single umbilical cord given with the mother’s consent 
and injected into the sub-tenon space of the eye. Only one eye was tested per individual 
and results were compared between the injected and non-injected eyes. These patients 
were followed for 6-months receiving an extensive panel of ophthalmic testing at one 
month intervals. Once injected, the MSC’s are assumed to work as an anti-inflammatory 
agent, help nourish and maintain the retinal pigment epithelium and reactive dormant rod 
photoreceptor cells. Significant improvements to rate of photoreceptor loss or 
maintenance of progression were seen in a majority of injected patients. The 
photoreceptors of multiple patients regained thickness in the inner rings, 1 through 3, and 
showed improvement in visual functioning, however, the outer fourth and fifth rings 
showed little to no improvement throughout the testing pool. However, it is known that 
most forms of RP develop from the outer periphery vision inward so it is likely these 
cells had already undergone apoptosis. (Emin &uuml et al., 2020).    
Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells. Similar to the 
prior study, another team of researchers conducted trials with MSC’s, however, instead of 
performing surgery or injection into the sub-tenon space, the cells were introduced into 




individuals, all suffering from late stage clinical RP. Results were similar to those when 
the treatment was injected, however, the cells effectiveness was for a slightly shorter 
duration. In this study, 96.9% of patients improved or maintained vision 1 month after 
infusion. Some patients experienced vision losses, however vision loss is to be expected 
in individuals with RP, and likely did not indicate negative effects, rather no positive 
results. The positive effects for most diminished after three – months post infusion when 
most stopped experiencing visual gains. However, 81.3% patients maintained the results 
of improved vision throughout the twelve month trial period. With no serious adverse 
effects in any patients, this study indicated the safety of intravenous MSC injection, as 
well as the potential positive effects for patients suffering with multiple forms of retinitis 












RETINITIS PIGMENTOSA TREATMENT DISCUSSION 
Current Stages of Experimental Treatments 
 This section covers the current state of treatments concerning Retinitis 
Pigmentosa followed by my suggestion of a future treatment. While some treatment 
options may be better than others, each treatment discussed below holds the potential to 
help those struggling with Retinitis Pigmentosa. Generally, those first approved from 
clinical trial will likely be used until better treatment methods are found. However, some 
are far closer than others to clinical release. One antioxidant treatment, Vitamin A 
palmitate, is currently in use as a treatment option for patients suffering from most forms 
of retinitis pigmentosa but unfortunately, after years of study, no conclusive or significant 
positive effects have been indicated. Currently there are no antioxidant cocktails in 
clinical study. Therefore, of the treatments discussed we are least likely to see them used 
in the near future. In order to do so researchers will first need to solve problems such as 
which antioxidants to include, amounts of each, and best method of administration.  
 Gene therapy for retinitis pigmentosa, conversely, has recently entered very early 
clinical trial stages in specific retinitis pigmentosa patients. As earlier discussed, some 
patients housing X-linked PRGR mutations showed positive results when treated with 
AAV8-coRPGR gene therapy. Mice, rats, and dogs with PDE6A and PDE6B mutations 
have shown gains in visual functioning through optogenetic mediated and AVV- Vector 




large animal species, the initial trials in x-linked RPGR patients showed that through sub-
retinal injection the gene therapy could delay photoreceptor death. Also, with the 
additional information from the trials indicating the optimal dosage of this treatment it is 
likely to see great gains in the near future, but is still not yet effective for treating this 
specific disorder.  
 Of the all the treatments discussed, stem cell therapy appears to be the closest to 
clinical approval. In both forms of clinical treatment, subretinal injection of MSC’s and 
intravenous infusion of MSC’s, significant positive results indicating the slowing of 
photoreceptor cell death and even the revival of dormant cells were seen with very few if 
any adverse side effects. Based on their relative success and lack of serious adverse 
effects we will likely see these forms of treatment approved soon.  
Adverse Effects of Treatments 
 It is also important to consider the adverse effects of each treatment. It is difficult 
to discuss those of the antioxidant treatment as the cocktails were studied in mice, and we 
do not yet know how they will react with the human body. Additionally, while Vitamin A 
palmitate is not known to have any serious adverse effects, it has also not been proved to 
be an effective form of treatment. However, other forms of experimental treatment have 
caused serious side effects which could lead to the loss of vision in some cases, most 
occurring in gene therapy treatment approaches. Within the study utilizing PDE6A dog’s 
serious complication from injection occurred including retinal separation and rosette 
formation. The human X-linked trials also had adverse effects, although less serious, 
reporting blebs, or fluid filled blisters on the surface of the eye, at the injection site. Post 




forms of therapy could ultimately restore vision, the risks seem to be greater with the 
method of administration currently used. However, injection into the sub-tenon space, as 
completed by the Wharton’s jelly derived stem cell trial, could decrease the number of 
adverse effects seen as the patients in these trials did not experience any severe adverse 
effects, nor did those administered intravenous MSC’s.  
Unknown Long Term Effects of All Treatments. It is also important to note that 
researchers are unsure of the long term effects of all stated experimental trials. Once 
again, antioxidants are difficult to discuss as these treatment approaches have not yet 
been tested in humans, but there could be complications due to a buildup of introduced 
vitamins and foreign materials.  
In regard to stem cell therapy treatment, these therapies could cause the 
development of severe long term side effects as it would currently require regular 
treatments. It has been stated in both studies that the effects of the initial injection will 
not remain for extended periods of time, requiring multiple procedures in order to 
maintain vision. Both methods cited few adverse side effects, however, with repeated and 
continued use this may not be the case. With subretinal injection evidence indicated 
benefits were highest up to six months and intravenous up to three. Both papers discussed 
issues that could arise from the rapid nature of proliferation in stem cells. If these cells 
were to migrate to undesired areas and build up in inappropriate locations, this could 
cause a slew of issues for other systems. Also, with additional therapies injection sites 
become more at risk for complications while sub- tenon injection seems to be a highly 
beneficial method without the issues of sub-retinal injections experienced, it is unknown 




Similarly, to stem cell therapies, gene therapy if completed successfully would 
likely require multiple procedures to re-introduce the desired vector. Additionally, 
patients may experience unpredictable adverse effects several months after treatment, 
which is currently unknown due to the early stages of clinical trial many gene therapies 
are in.  
Implications of Early Age Onset and Treatment 
 One of the difficulties of any treatment targeting Retinitis Pigmentosa is both the 
young age of onset and rapid nature of photoreceptor loss. Photoreceptor loss due the 
disease can begin to occur in young adults although age of onset varies widely, often 
correlating to which gene is affected. With the discovery of more of the genes which 
induce retinitis pigmentosa diseases, early diagnosis has become far more common. 
However, once noticeable symptoms begin to be displayed many rod photoreceptors have 
been lost due to the disease. As discussed earlier, no current treatments exist that have the 
ability to rescue lost photoreceptors after apoptosis has occurred and only stem cell 
therapy has been seen to rescue those that have entered dormancy. This issue was 
exemplified in the gene therapy treatment of the PDE6A dogs as the injections worked 
most effectively at approximately 36 days post birth and in only still developing eyes. 
This creates difficulties for researchers as often young patients would benefit most from 
and be ideal patients for treatments designed to stop photoreceptor death as they would be 
in early stages of disease progression. However, experimental clinical testing is not often 
conducted on children, as parents would be unlikely to allow their children who have not 
yet experienced loss of vision to participate. This calls for a treatment which would be 




created children could take these supplements orally, removing the need for multiple 
clinical visits, injections, or surgeries. Intravenous input of stem cells also appears to be a 
more child friendly approach when compared to the subretinal injection of gene therapy, 
or sub-tenon injection of stem cells, decreasing the need for doctor visits and invasive 
procedures.  
Convenience and Requirement of Recurring Visits 
 With treatments one must consider the convenience of treatment as well as the 
requirement of physician administration and therefore doctors’ visits in order to 
administer treatment. In the case of a discovered antioxidant treatment likely they could 
be taken orally requiring only a prescription appointment and check-in intervals to 
determine the effectiveness of treatment. This set-up is far different than that of both gene 
therapy and stem cell therapy treatments, although the duration between each treatment 
may vary, both will require repeated injection or infusion in order to maintain decrease of 
photoreceptor loss or visual gains, this means routine doctors’ visits for the patient as 
well as repeated potentially invasive treatments to see sustaining positive effects.  
Patient Exclusions of Each Therapy  
 One of the most attractive features of antioxidant therapy is its ability to 
potentially decrease the loss of photoreceptor cells in all retinitis pigmentosa patients. 
This treatment targets patients with remaining vision as it strives to mediate a 
consequence of rod photoreceptor loss, instead of the more complicated cause of loss. In 
theory, most retinitis pigmentosa diseases do not target the cone cells, but their death is 




cones were able to be preserved through these treatments, patients would only lose 
peripheral vision as opposed to complete vision loss. If a treatment is completed, every 
patient suffering from early stage retinitis pigmentosa and oxidative damage may be able 
to have the remaining vision produced by cone cells. Though, any patients with complete 
blindness, or substantial loss of cone photoreceptors could not be helped through this 
treatment. 
 Similarly, stem cell therapy strives to serve a large percentage of retinitis 
pigmentosa patients, the treatments can be used for those suffering from multiple 
different forms of RP resulting from several different gene mutations. This form of 
treatment is slightly less inclusive than antioxidants. All treatment subjects were required 
to have no previous history of treatment mediation due to complications that could be 
produced from interacting with previous interventions. Additionally, yet again, patients 
already suffering from complete blindness or dramatically reduced vision, are unlikely to 
see benefits from these treatments due to their inability to restore dead photoreceptor 
cells.  
 Conversely, gene therapy approaches are often highly targeted to singular genes 
and mutations. The genetic nature of the disease makes it a crucial target for gene 
therapy, however since the group of diseases is so diverse, these methods must be highly 
targeted and will only serve small percentages of retinitis pigmentosa patients per each 
targeted therapy. As previously discussed, human trials have begun on patients displaying 
X-linked PRGR mutations. If the treatment described does get approved by the FDA then 
it will only benefit those with this mutation which include only relatively young males, 




exclude many older patients with more progressive stages of retinitis pigmentosa due to 
other health concerns. 
Conclusion of Most Promising Therapy 
 With the lack of a treatment that is currently in use to help Retinitis Pigmentosa 
patients slow the loss of photoreceptor cells or regain lost site, the success of any of these 
treatments would be a substantial triumph for patients and researchers alike. However, 
they are not all created equal and through critical evaluation, stem cell therapy with 
MCS’s through intravenous infusion appears to be the most promising. This treatment 
can not only service a wide range of patients with few adverse effects, but also will be 
able to potentially halt the rapid decline of photoreceptor cells. It also appears to be the 
closest to approval and minimally invasive. It is difficult to dismiss treatment with 
antioxidants as it could produce similar effects and would likely rank better in all of the 
categories previously listed. However, its development is behind the other treatments and 
thus has a more uncertain future. Additionally, gene therapy would likely provide better 
results and could even restore lost vision, but with its highly targeted nature, can only 
improve the lives of small portions of the retinitis pigmentosa community per perfected 
treatment. When comparing the two forms of MSC injection, sub-tenon injection of 
Wharton’s Jelly derived MSC’s does produce longer lasting results of photoreceptor 
death decrease but requires time consuming culture of materials and eye injection, which 
could lead to increased complications and adverse side effects with continuous injections. 
 In additional clinical trials, if intravenous stem cell therapy continues to be proven 
safe and effective, trials will likely expand to broader age ranges and patients with more 




through testing, more funds dedicated to the culture and distribution of intravenous 
umbilical cord MSC’s, and greater awareness of this form of treatment, I predict this 
treatment modality could be quickly heading to clinical approval. This would allow a 
majority of retinitis pigmentosa patients a method of treatment which may halt disease 
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